BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

Volver

Resultados 65 resultados LastUpdate Última actualización 13/11/2018 [15:38:00] pdf PDF




Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 3 nextPage   Mostrar por página


HUMANIZED ANTIBODIES TO AMYLOID BETA

NºPublicación: PH12015500507A1 05/11/2018

Solicitante:
AC IMMUNE SA [CH]
GENENTECH INC [US]

Resumen de: PH12015500507A1

The present application is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.



traducir


 

Antibody-Based Molecules Selective for the {P}Ser404 Epitope of Tau and Their Uses in the Diagnosis and Treatment of Tauopathy

NºPublicación: US2018312608A1 01/11/2018

Solicitante:
UNIV NEW YORK [US]

Resumen de: US2018312608A1

The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to the {p}Ser404 Epitope of Tau. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody -based molecules of the present invention have particular utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.



traducir


 

METHODS FOR APOLIPOPROTEIN DETECTION

NºPublicación: US2018313854A1 01/11/2018

Solicitante:
BIOCROSS S L [ES]
INST DE SALUD CARLOS III [ES]
CENTRO DE INVESTIG BIOMEDICA EN RED DE ENFERMEDADES NEURODEGENERATIVAS [ES]

Resumen de: US2018313854A1

The present invention relates to methods for the detection and quantification of apolipoproteins and isoforms thereof in a sample, as well as to predictive methods of the probability of neurodegenerative or cardiovascular disease development based on apolipoprotein levels as determined by the detection methods of the invention.



traducir


 

TAU-BINDING ANTIBODIES

NºPublicación: EA201890169A1 31/10/2018

Solicitante:
\u042E\u0421\u0411 \u0411\u0418\u041E\u0424\u0410\u0420\u041C\u0410 \u0421\u041F\u0420\u041B

Resumen de: WO2017005732A1

The present invention relates to Tau-binding antibodies and binding fragments thereof.



traducir


 

IMPROVED DEVICES, SYSTEMS AND METHODS FOR DETECTING A BILATERAL DIFFERENTIAL IN OLFACTORY DETECTION THRESHOLD FOR PURE ODORANTS

NºPublicación: EP3395387A1 31/10/2018

Solicitante:
INSPIRED TECH INC [US]

Resumen de: EP3395387A1

The present invention concerns a method for ruling out the presence of Alzheimer's disease in a patient by measuring the sensitivity of the left and right olfactory bulbs to substances that only stimulate the first cranial nerve and not the 5th cranial nerve, comprising: providing at least two pure odorants, the pure odorants capable of stimulating the first cranial nerve and not the 5th cranial nerve; establishing an introduction order for the at least two pure odorants; introducing pure odorant-infused air in the established introduction order to the patient's first nostril; measuring and recording a pure odorant detection metric for each of the pure odorant-infused air introductions, the pure odorant detection metric comprising the time and/or the number of breaths required by the patient to reach a pure odorant detection threshold with the first nostril for each of the at least two pure odorants and switching from a first pure odorant in the established introduction order to the next pure odorant in the established introduction order after the patient reaches the pure odorant detection threshold for the first pure odorant; introducing pure odorant-infused air in the established introduction order to the patient's second nostril; measuring and recording a pure odorant detection metric for each of the pure odorant-infused air introductions, the pure odorant detection metric comprising the time and/or the number of breaths required by the patient to reach a pure odorant dete



traducir


 

System and method for protein corona sensor array for early detection of diseases

NºPublicación: GB2561940A 31/10/2018

Solicitante:
BRIGHAM & WOMENS HOSPITAL INC [US]

Resumen de: GB2561940A

The present disclosure provides sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.



traducir


 

METHOD OF IDENTIFYING NOVEL PROTEIN AGGREGATION INHIBITORS BASED ON CHEMICAL KINETICS

NºPublicación: US2018306813A1 25/10/2018

Solicitante:
CAMBRIDGE ENTERPRISE LTD [GB]

Resumen de: US2018306813A1

The present invention relates to methods of identifying pharmacophores and inhibitors against protein aggregation. The present invention also provides pharmacophores themselves and medical uses of agents in the treatment of Alzheimer's.



traducir


 

SYSTEM AND METHOD FOR MULTI-PARAMETER SPECTROSCOPY

NºPublicación: US2018306716A1 25/10/2018

Solicitante:
NXGEN PARTNERS IP LLC [US]

Resumen de: US2018306716A1

An apparatus for detecting a material within a sample includes a light emitting unit for directing at least one light beam through the sample. A plurality of units receive the light beam that has passed through the sample and performs a spectroscopic analysis of the sample based on the received light beam. Each of the plurality of units analyze a different parameter with respect to the sample a provide a separate output signal with respect to the analysis. A processor detects the material with respect each of the provided separate output signals.



traducir


 

NOVEL LIGANDS FOR PREVENTION OF NEUROTOXICITY OF THE ALZHEIMER'S DISEASE RELATED AMYLOID-BETA PEPTIDE

NºPublicación: US2018305404A1 25/10/2018

Solicitante:
ALPHABETA AB [SE]

Resumen de: US2018305404A1

The present invention relates to the field of molecular biochemistry and medicine, and in particular to ligands comprising modified amino acid residues, targeting the amyloid-β peptide associated with Alzheimer's disease for prevention of aggregation, neurotoxicity and use thereof as drugs for treatment of Alzheimer's disease.



traducir


 

EARLY-STAGE ALZHEIMER'S DISEASE AUTOANTIBODY BIOMARKERS, TARGET ANTIGENS AND DIAGNOSTIC USES THEREOF

NºPublicación: EP3390700A1 24/10/2018

Solicitante:
ROWAN UNIV [US]

Resumen de: WO2017106338A1

The present invention provides methods, compositions and kits for the detection of Early-Stage Alzheimer's disease (AD) autoantibody biomarkers, for the diagnosis of Early-Stage AD, for the identification of a subject at risk for developing Early-Stage AD, and for the generation of patient-specific Early-Stage AD autoantibody biomarker profiles.



traducir


 

SYSTEMS AND METHODS FOR QUANTITATIVELY CHARACTERIZING ALZHEIMER'S DISEASE RISK EVENTS BASED ON MULTIMODAL BIOMARKER DATA

NºPublicación: EP3389479A1 24/10/2018

Solicitante:
THE MEDICAL COLLEGE OF WISCONSIN INC [US]

Resumen de: WO2017106498A1

Systems and methods are described for computing a quantitative index that characterizes Alzheimer's disease ("AD") risk events based on a temporally ordered sequence of biomarker events. In general, the systems and methods described here implement a modified event-based probabilistic ("EBP") model to calculate the risk index from biomarker data.



traducir


 

METHODS FOR APOLIPOPROTEIN DETECTION

NºPublicación: CN108700593A 23/10/2018

Solicitante:
\u62DC\u5965\u514B\u7F57\u65AF\u516C\u53F8,
\u5361\u6D1B\u65AF\u4E09\u4E16\u4FDD\u5065\u4E2D\u5FC3,
\u795E\u7ECF\u9000\u884C\u6027\u75BE\u75C5\u7F51\u7EDC\u751F\u7269\u533B\u5B66\u7814\u7A76\u4E2D\u5FC3

Resumen de: EP3163303A1

The present invention relates to methods for the detection and quantification of apolipoproteins and isoforms thereof in a sample, as well as to predictive methods of the probability of neurodegenerative or cardiovascular disease development based on apolipoprotein levels as determined by the detection methods of the invention.



traducir


 

HUMANIZED ANTIBODIES

NºPublicación: CN108699139A 23/10/2018

Solicitante:
\u524D\u4F53\u751F\u7269\u836F\u7269\u80A1\u4EFD\u516C\u53F8

Resumen de: WO2017009459A2

The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (Αβ N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of Αβ N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.



traducir


 

ANTIBODIES TO TAU

NºPublicación: RU2018132044A 19/10/2018

Solicitante:
\u0412\u0410\u0428\u0418\u041D\u0413\u0422\u041E\u041D \u042E\u041D\u0418\u0412\u0415\u0420\u0421\u0418\u0422\u0418

Resumen de: WO2014008404A1

This invention relates to antibodies to tau and methods of use thereof.



traducir


 

Chimeric Protein in the Treatment of Amyloidosis

NºPublicación: US2018298071A1 18/10/2018

Solicitante:
LAB FRANCAIS DU FRACTIONNEMENT [FR]

Resumen de: US2018298071A1

The present invention relates to a chimeric protein comprising at least one human amyloid P component and at least one fragment of an Fc region of a human antibody, the human amyloid P component and the fragment of an Fc region with which it is associated being bound to each other by means of a hinge region.



traducir


 

ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE TOXIC OLIGOMERIC FORMS OF TAU

NºPublicación: US2018298086A1 18/10/2018

Solicitante:
UNIV ARIZONA STATE [US]

Resumen de: US2018298086A1

The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomeric tau, fibrillar tau or non-disease associated forms of tau.



traducir


 

A peptide probe for early diagnosis of alzheimer's disease

NºPublicación: KR20180112639A 12/10/2018

Solicitante:
INDUSTRY ACADEMIC COOPERATION FOUNDATION CHOSUN UNIV [KR]
GWANGJU INST SCIENCE & TECH [KR]

Resumen de: KR20180112639A

본 발명은 알츠하이머성 치매환자 특이적 자가항체와 결합을 할 수 있는 펩타이드 프로브에 관한 것이다. 본 발명의 펩타이드 프로브는 혈액 내 자가항체 검출을 통해 알츠하이머 조기진단 바이오마커로써 사용될 수 있다. 또한, 본 발명의 펩타이드 프로브는 알츠하이머성 치매의 조기 진단을 위한 키트의 제조에 이용될 수 있으며, 알츠하이머성 경도인지장애 환자 또는 알츠하이머성 치매환자에 특이적으로 존재하는 자가항체 바이오마커를 스크리닝 하는 데 이용될 수 있다.



traducir


 

TRANSGENIC PORCINE MODEL FOR ALZHEIMER'S DISEASE AND PRODUCING METHOD THEREOF

NºPublicación: KR20180112558A 12/10/2018

Solicitante:
MEDIFRON DBT INC [KR]

Resumen de: KR20180112558A

본 발명은 재조합 렌티 바이러스를 이용한 알츠하이머병 형질전환 돼지 모델 제조방법 및 이를 통해 제작된 알츠하이머병 형질전환 돼지 모델에 관한 것으로, 본 발명의 제조방법으로 제조된 알츠하이머병 형질전환 돼지 모델은 알츠하이머병의 발병 요인 유전자가 복합적으로 발현하고 기억 및 학습 능력의 저하 및 인접 신경세포를 파괴하는 성상세포의 비정상적인 증가가 유도되었다. 따라서, 이러한 알츠하이머병 형질전환 돼지 모델은 알츠하이머병 치료제 개발에 유용하게 사용할 수 있다.



traducir


 

ANTIBODY ARRAY FOR MEASURING A PANEL OF AMYLOIDS

NºPublicación: US2018292419A1 11/10/2018

Solicitante:
MESO SCALE TECHNOLOGIES LLC [US]

Resumen de: US2018292419A1

Described are assay methods, modules and kits useful in the detection, treatment and/or prevention of dementia and related conditions, including but not limited to Alzheimer's disease and mild cognitive disorders.



traducir


 

NOVEL SLICE CULTURES AND METHODS FOR DIAGNOSING NEURONAL DEGENERATION DISEASES

NºPublicación: US2018292390A1 11/10/2018

Solicitante:
ROWAN UNIV [US]

Resumen de: US2018292390A1

The present invention relates novel slice culture systems which provide a quick, simple, and effective tool for investigating pathological changes associated with AD. Also provided are methods of diagnosing AD and identifying potentially therapeutic compounds.



traducir


 

Antibodies recognizing Tau

NºPublicación: AU2017259038A1 11/10/2018

Solicitante:
PROTHENA BIOSCIENCES LTD

Resumen de: AU2017259038A1

The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.



traducir


 

Animal model of neurodegenerative disease

NºPublicación: GB2561215A 10/10/2018

Solicitante:
NELSON MANDELA METROPOLITAN UNIV [ZA]

Resumen de: GB2561215A

An animal (e.g. rat) model of neurodegenerative disease, preferably selected from Alzheimer's disease, Parkinson's disease, Lewy body dementia and Amyotrophic lateral sclerosis (ALS), based on the administration of a single dose of beta-N-­methyl amino-L-alanine (BMAA), to induce the neurodegenerative disease. The single dose of BMAA is administered between postnatal day 1 to 6. Also claimed are a non-human animal suitable for use in a method of testing a compound as a treatment of a neurodegenerative disease and a kit comprising BMAA and instruction for its use.



traducir


 

COMPOUND FOR SPECIFIC BINDING WITH AMYLOID PROTEIN

NºPublicación: EP3385266A1 10/10/2018

Solicitante:
NEUBORON MEDTECH LTD [CN]

Resumen de: EP3385266A1

Provided is a compound for specifically binding to amyloid ²-protein. The compound has thereon a nuclide with a large thermal neutron capture cross section and the compound is capable of specifically binding to the amyloid ²-protein. The property of the compound allows it to be used in conjunction with a neutron capture therapy device to eliminate amyloid ²-protein. Similarly, when the compound is labelled with radioactive element 11 C, the compound can also be used in conjunction with PET/CT for determining the part of the brain where amyloid ²-protein is deposited, for diagnosing Alzheimer's disease. Also disclosed is a preparation process for the compound. The beneficial effect of the present disclosure is to make the therapy and diagnosis of Alzheimer's disease more targeted by providing the compound for specifically binding to amyloid ²-protein.



traducir


 

ANTIBODIES TO TAU

NºPublicación: CN108623682A 09/10/2018

Solicitante:
\u534E\u76DB\u987F\u5927\u5B66

Resumen de: WO2014008404A1

This invention relates to antibodies to tau and methods of use thereof.



traducir


 

COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER

Nº publicación: JP2018153184A 04/10/2018

Solicitante:
\u30D0\u30FC\u30B0 \u30A8\u30EB\u30A8\u30EB\u30B7\u30FC

Resumen de: WO2013134315A1

Methods for treatment and diagnosis of pervasive developmental disorders in humans are described.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver